The favorable effect of overweight or obese-level BMI on prolonging time to treatment failure, PFS, and OS has also been demonstrated for patients receiving anti-PD1/anti-PDL1 immunotherapy against melanoma, among other tumors [156]. Here, CD274 is linked to melanoma.